Menopause is a pivotal life stage for every woman, marking the end of reproductive years and bringing with it a range of ...

At some point in their lifetimes, approximately one out of every eight women in the United States will be diagnosed with breast cancer. That estimate from the American Cancer Society becomes even more ...

In this video, Erica L. Mayer, MD, MPH, director of breast cancer clinical research at Dana-Farber Cancer Institute, discusses results of the TRADE study, which she presented at ASCO Annual ...

I got breast cancer at 30. Now, because of my treatment, I have to wait 5 to 10 years to have kids, and I'm mourning the ...

Male patients with ER+ breast cancer tend to have grade 2 or 3 tumors, stage II or III disease, and progesterone receptor-positivity compared to female patients.

Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer.

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

ASCO Data Shows New Therapy Delays Breast Cancer Progression and May Improve Quality of Life for Women with Hormone ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...